Literature DB >> 21118970

Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis.

Huijun Chen1, Xufeng Wu, Zhixing K Pan, Shuang Huang.   

Abstract

Ovarian cancer is mainly confined in peritoneal cavity and its metastasis is often associated with the formation of malignant ascites. As lysophosphatidic acid (LPA) is present at high levels in ascites of ovarian cancer patients and potently stimulates cell migration, we reason that LPA-stimulated cell migration may play an important role in ovarian cancer metastasis. Here, we show that only ovarian cancer cell lines with LPA migratory response undergo peritoneal metastatic colonization. LPA-stimulated cell migration is required for metastatic colonization because knockdown of LPA receptor subtype 1 (LPAR(1)) abolishes this event. However, the difference in metastatic potentials is not caused by the absence of LPAR(1) because both metastatic and nonmetastatic lines express similar levels of LPAR(1). Instead, we find that LPA can activate Rac only in metastatic cells and that metastatic colonization of ovarian cancer cells necessitates Rac activity. These results thus suggest that LPA-induced Rac activation is a prerequisite for ovarian cancer metastasis. In metastatic cells, Rac activation is facilitated by SOS1/EPS8/ABI1 tri-complex and the integrity of this tri-complex is essential for LPA-stimulated cell migration and metastatic colonization. We show that at least 1 member of SOS1/EPS8/ABI1 tri-complex is absent in nonmetastatic ovarian cancer cells and reexpressing the missing one conferred them with metastatic capability. Importantly, coexpression of SOS1, EPS8, and ABI1, but not of any individual member of SOS1/EPS8/ABI1 tri-complex, correlates with advanced stages and shorter survival of ovarian cancer patients. Our study implicates that the integrity of SOS1/EPS8/ABI1 tri-complex is a determinant of ovarian cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21118970      PMCID: PMC3059077          DOI: 10.1158/0008-5472.CAN-10-2394

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  Cell migration: integrating signals from front to back.

Authors:  Anne J Ridley; Martin A Schwartz; Keith Burridge; Richard A Firtel; Mark H Ginsberg; Gary Borisy; J Thomas Parsons; Alan Rick Horwitz
Journal:  Science       Date:  2003-12-05       Impact factor: 47.728

2.  IRSp53/Eps8 complex is important for positive regulation of Rac and cancer cell motility/invasiveness.

Authors:  Yosuke Funato; Takeshi Terabayashi; Naoko Suenaga; Motoharu Seiki; Tadaomi Takenawa; Hiroaki Miki
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

3.  Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia.

Authors:  C D Nobes; A Hall
Journal:  Cell       Date:  1995-04-07       Impact factor: 41.582

4.  Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells.

Authors:  Xianjun Fang; Shuangxing Yu; Robert C Bast; Shuying Liu; Hong-Ji Xu; Shi-Xue Hu; Ruth LaPushin; Francois X Claret; Bharat B Aggarwal; Yiling Lu; Gordon B Mills
Journal:  J Biol Chem       Date:  2003-12-11       Impact factor: 5.157

5.  Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.

Authors:  Dafang Bian; Shibing Su; Chitladda Mahanivong; Robert K Cheng; Qiwei Han; Zhixing K Pan; Peiqing Sun; Shuang Huang
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

6.  Metastatic patterns in histologic variants of ovarian cancer. An autopsy study.

Authors:  P G Rose; M S Piver; Y Tsukada; T S Lau
Journal:  Cancer       Date:  1989-10-01       Impact factor: 6.860

7.  Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.

Authors:  Kotaro Hama; Junken Aoki; Masahiro Fukaya; Yasuhiro Kishi; Teruyuki Sakai; Rika Suzuki; Hideo Ohta; Takao Yamori; Masahiko Watanabe; Jerold Chun; Hiroyuki Arai
Journal:  J Biol Chem       Date:  2004-01-26       Impact factor: 5.157

8.  A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells.

Authors:  Saubhik Sengupta; Yi-Jin Xiao; Yan Xu
Journal:  FASEB J       Date:  2003-06-03       Impact factor: 5.191

9.  Lysophospholipids activate ovarian and breast cancer cells.

Authors:  Y Xu; X J Fang; G Casey; G B Mills
Journal:  Biochem J       Date:  1995-08-01       Impact factor: 3.857

10.  Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation.

Authors:  Patrizia Sini; Angela Cannas; Anthony J Koleske; Pier Paolo Di Fiore; Giorgio Scita
Journal:  Nat Cell Biol       Date:  2004-02-22       Impact factor: 28.824

View more
  50 in total

1.  Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.

Authors:  Abir Mukherjee; Jinhua Wu; Suzanne Barbour; Xianjun Fang
Journal:  J Biol Chem       Date:  2012-06-03       Impact factor: 5.157

2.  Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Authors:  Richard Marcotte; Kevin R Brown; Fernando Suarez; Azin Sayad; Konstantina Karamboulas; Paul M Krzyzanowski; Fabrice Sircoulomb; Mauricio Medrano; Yaroslav Fedyshyn; Judice L Y Koh; Dewald van Dyk; Bodhana Fedyshyn; Marianna Luhova; Glauber C Brito; Franco J Vizeacoumar; Frederick S Vizeacoumar; Alessandro Datti; Dahlia Kasimer; Alla Buzina; Patricia Mero; Christine Misquitta; Josee Normand; Maliha Haider; Troy Ketela; Jeffrey L Wrana; Robert Rottapel; Benjamin G Neel; Jason Moffat
Journal:  Cancer Discov       Date:  2011-12-29       Impact factor: 39.397

Review 3.  Abi1, a critical molecule coordinating actin cytoskeleton reorganization with PI-3 kinase and growth signaling.

Authors:  Leszek Kotula
Journal:  FEBS Lett       Date:  2012-05-19       Impact factor: 4.124

4.  ADP-ribosylation factor-like 4C (ARL4C), a novel ovarian cancer metastasis suppressor, identified by integrated genomics.

Authors:  Dan Su; Dionyssios Katsaros; Shenhua Xu; Haiyan Xu; Yun Gao; Nicoletta Biglia; Jianguo Feng; Lisha Ying; Ping Zhang; Chiara Benedetto; Herbert Yu
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

Review 5.  BAR domain proteins regulate Rho GTPase signaling.

Authors:  Pontus Aspenström
Journal:  Small GTPases       Date:  2014

Review 6.  GPCRs and cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

7.  Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Huining Kang; Carla S Wilson; Richard C Harvey; I-Ming Chen; Maurice H Murphy; Susan R Atlas; Edward J Bedrick; Meenakshi Devidas; Andrew J Carroll; Blaine W Robinson; Ronald W Stam; Maria G Valsecchi; Rob Pieters; Nyla A Heerema; Joanne M Hilden; Carolyn A Felix; Gregory H Reaman; Bruce Camitta; Naomi Winick; William L Carroll; ZoAnn E Dreyer; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

8.  Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton.

Authors:  Sajjad Hossain; Patrycja M Dubielecka; Aleksander F Sikorski; Raymond B Birge; Leszek Kotula
Journal:  Genes Cancer       Date:  2012-05

9.  [Abelson interactor 1 (Abi1) in colorectal cancer. From synaptic plasticity to tumor cell migration].

Authors:  K Steinestel; F Gläsle; S Brüderlein; J Steinestel; C Pröpper; P Möller
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

10.  Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen.

Authors:  Xiaoling Xie; Yuxing Hu; Tong Ye; Yiran Chen; Lijuan Zhou; Feng Li; Xiaobo Xi; Shuang Wang; Yanjie He; Xiaoyong Gao; Wei Wei; Guanghui Ma; Yuhua Li
Journal:  Nat Biomed Eng       Date:  2020-10-12       Impact factor: 25.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.